Search Videos and More
News
Adolescent Glioma Subtype Responds to CDK4/6 Inhibitor
CDK4/6 inhibitors, which are already FDA approved for the treatment of other forms of cancer, show early signs of promise in the treatment of a subtype of pediatric high-grade glioma, according to new research from Dana-Farber Cancer Institute and the Institute of Cancer Research in London.
News
Dana-Farber President and CEO Laurie Glimcher, MD, Announces Her Plans to Step Down Capping a Highly Successful Tenure Marked with Discovery and Innovation
Acclaimed medical oncologist and researcher Benjamin Ebert, MD, PhD, appointed to lead the world-renowned cancer center
News
Dana-Farber Research News 9.01.2024
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from August 1 through August 15.
News
Early Action, Better Outcomes: Transforming Cancer Prevention
For more than 100 years, health advocates have spread the message that, with cancer, patience is not a virtue.
News
Dana-Farber Research Publication 8.15.2024
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from July 16 through July 31.
News
FDA Approves New Therapy for Glioma Patients for First Time in Decades
Vorasidenib has been approved by the U.S. Food and Drug Administration (FDA) for patients with Grade 2 gliomas with IDH1 or IDH2 mutations.
News
Dana-Farber Research Publication 8.01.2024
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from July 1 through July 15.
News
Rethinking Breast Cancer: Illuminating New Paths to Treatment and Prevention
Clinical trial data can often help scientists find answers in their quest to treat cancers. Sometimes, it can also reveal surprising new evidence about the drivers of disease, illuminating a new tactic for preventing cancer in the first place.
News
Researchers Devise Novel Solution to Preventing Relapse after CAR T-cell Therapy
Even as they have revolutionized the treatment of certain forms of cancer, CAR T-cell therapies have been shadowed by a significant limitation: many patients, including those whose cancer goes into full remission, eventually relapse. In a new study, Dana-Farber Cancer Institute researchers report on a technique with the potential to eliminate that problem.
News
Bringing Advanced Medicines for Multiple Myeloma into Reach for All
Multiple myeloma is a cancer of the bone marrow. It affects plasma cells, which are mature forms of blood cells called B-lymphocytes.
News
In a First, Immune Checkpoint Inhibitors Show Effectiveness in Metastatic Colorectal Cancer
In trial after clinical trial, metastatic colorectal cancer has been largely undeterred by immune checkpoint inhibitors.
News
U.S. News & World Report names Dana-Farber Brigham Cancer Center Among Nation’s Best for 2024-2025
For the 24th consecutive year, Dana-Farber Brigham Cancer Center has been recognized as a Best Hospital for cancer care by U.S. News & World Report.